Biologiske behandlinger af andre dermatologiske sygdomme end psoriasis

Robert Gniadecki; Lone Skov

Biologiske behandlinger af andre dermatologiske sygdomme end psoriasis

Robert Gniadecki, Lone Skov

Abstract

Psoriasis is the only disease in dermatology where biologics have been studied in placebo controlled trials. However, drugs have been used for several other indications in dermatology, e.g. pyoderma gangrenosum and pemphigus. We give a brief overview of the indications for biologics in skin diseases.

Bidragets oversatte titel	Biologics in skin diseases other than psoriasis
Originalsprog	Dansk
Tidsskrift	Ugeskrift for Laeger
Vol/bind	170
Udgave nummer	24
Sider (fra-til)	2126-8
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 9 jun. 2008

Emneord

Acne Vulgaris
Adalimumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Behcet Syndrome
Dermatologic Agents
Etanercept
Humans
Immunoglobulin G
Immunologic Factors
Infliximab
Interferons
Lymphoma, T-Cell, Cutaneous
Pemphigus
Pyoderma Gangrenosum
Receptors, Tumor Necrosis Factor
Rituximab
Skin Diseases
Skin Neoplasms

Citationsformater

@article{3f3ada4214cc447ab2f6add8eb822c8c,

title = "Biologiske behandlinger af andre dermatologiske sygdomme end psoriasis",

abstract = "Psoriasis is the only disease in dermatology where biologics have been studied in placebo controlled trials. However, drugs have been used for several other indications in dermatology, e.g. pyoderma gangrenosum and pemphigus. We give a brief overview of the indications for biologics in skin diseases.",

keywords = "Acne Vulgaris, Adalimumab, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Agents, Behcet Syndrome, Dermatologic Agents, Etanercept, Humans, Immunoglobulin G, Immunologic Factors, Infliximab, Interferons, Lymphoma, T-Cell, Cutaneous, Pemphigus, Pyoderma Gangrenosum, Receptors, Tumor Necrosis Factor, Rituximab, Skin Diseases, Skin Neoplasms",

author = "Robert Gniadecki and Lone Skov",

year = "2008",

month = jun,

day = "9",

language = "Dansk",

volume = "170",

pages = "2126--8",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "24",

}

TY - JOUR

T1 - Biologiske behandlinger af andre dermatologiske sygdomme end psoriasis

AU - Gniadecki, Robert

AU - Skov, Lone

PY - 2008/6/9

Y1 - 2008/6/9

N2 - Psoriasis is the only disease in dermatology where biologics have been studied in placebo controlled trials. However, drugs have been used for several other indications in dermatology, e.g. pyoderma gangrenosum and pemphigus. We give a brief overview of the indications for biologics in skin diseases.

AB - Psoriasis is the only disease in dermatology where biologics have been studied in placebo controlled trials. However, drugs have been used for several other indications in dermatology, e.g. pyoderma gangrenosum and pemphigus. We give a brief overview of the indications for biologics in skin diseases.

KW - Acne Vulgaris

KW - Adalimumab

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Antibodies, Monoclonal, Murine-Derived

KW - Antineoplastic Agents

KW - Behcet Syndrome

KW - Dermatologic Agents

KW - Etanercept

KW - Humans

KW - Immunoglobulin G

KW - Immunologic Factors

KW - Infliximab

KW - Interferons

KW - Lymphoma, T-Cell, Cutaneous

KW - Pemphigus

KW - Pyoderma Gangrenosum

KW - Receptors, Tumor Necrosis Factor

KW - Rituximab

KW - Skin Diseases

KW - Skin Neoplasms

M3 - Tidsskriftartikel

C2 - 18565293

SN - 0041-5782

VL - 170

SP - 2126

EP - 2128

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 24

ER -

Biologiske behandlinger af andre dermatologiske sygdomme end psoriasis

Abstract

Emneord

Fingeraftryk

Citationsformater